GBA
SGMO

Garrison Bradford & Associates’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Garrison Bradford & Associates’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,200
Closed -$221K – 115
2014
Q1 		$221K Buy
12,200
+200
+2% +$3.85K 0.21% 91
2013
Q4 		$167K Hold
12,000
– – 0.16% 94
2013
Q3 		$126K Hold
12,000
– – 0.13% 96
2013
Q2 		$94K Buy
+12,000
New +$105K 0.1% 104

Other funds holding SGMO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Garrison Bradford & Associates's SGMO Position: Q2 2014 in Review

Garrison Bradford & Associates sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2014, closing a stake of 12,200 shares — an estimated $221K sold.

Garrison Bradford & Associates first reported a position in SGMO in Q2 2013 and held it in 4 quarters. The position peaked at $221K in Q1 2014. 156 funds tracked by Wall St. Rank hold SGMO as of Q2 2014.

  • Garrison Bradford & Associates reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2014 after selling out during the quarter.
  • Garrison Bradford & Associates sold 12,200 SANGAMO THERAPEUTICS INC shares in Q2 2014, an estimated $221K.
  • Garrison Bradford & Associates first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 4 quarters.
  • Garrison Bradford & Associates's SANGAMO THERAPEUTICS INC position peaked at $221K in Q1 2014.
  • 156 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2014.

Based on Garrison Bradford & Associates's 13F filing for Q2 2014, filed 14 Jul 2014.